ArticleFrontiers in cellular and infection microbiology2026
Alarming levels of fluoroquinolone resistance among MDR-TB patients in Poland: molecular and phenotypic analysis.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fluoroquinolones (FQs) are a cornerstone of modern multidrug-resistant tuberculosis (MDR-TB) treatment, particularly within the WHO-recommended all-oral BPaLM regimen. The emergence of FQ-resistant Methods: We analyzed 240 drug-resistant MTB isolates (228 MDR and 12 rifampicin-resistant) collected nationwide. Phenotypic drug susceptibility testing (DST) was performed using the Bactec MGIT 960 system. Isolates demonstrating resistance to levofloxacin and/or moxifloxacin ( Results: Phenotypic FQ resistance was detected in an alarming 43.0% (104/240) of isolates. Mutational analysis revealed eight variants in the Conclusions: Our findings demonstrate a substantial and concerning burden of FQ resistance among MDR-TB strains in Poland, significantly exceeding global averages. The high prevalence of QRDR mutations and the dominance of the Beijing genotype highlight the urgent need for systematic molecular surveillance and rapid NGS-based diagnostics. Such measures are essential to ensure the effectiveness of the BPaLM regimen and prevent the further spread of highly drug-resistant TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.